Peptide Research Parameters & Dosing
A research dose belongs to a specific experiment: the compound, formulation, model, route, exposure time and measured outcome. A weekly amount in milligrams is not a cell-culture concentration, and a clinical medicine schedule does not establish a protocol for a research vial.
Updated 5 October 2026. This page explains how to read and record laboratory parameters. Products linked here are supplied for laboratory research.
Concentration, dose and vial content
Keep these quantities separate when extracting a method from a paper. A vial label describes the supplied amount; it does not specify how much an experiment should use. HPLC peak-area purity does not by itself establish the mass of peptide in the vial.
| Quantity | What to record |
|---|---|
| Mass concentration | Mass divided by solution volume, such as mg/mL. For a calculation example, 5 mg in 2 mL is 2.5 mg/mL; this is not a dosing recommendation. |
| Molar concentration | Amount of substance per volume, such as µM. Conversion from mg/mL requires the molecular weight of the actual compound and formulation. |
| Animal-study dose | The reported mass per body weight, route, species, frequency and duration. Do not transfer it directly to humans or a different model. |
| Clinical dose | The investigated or authorised medicine, formulation and population. A research reagent is not interchangeable with that medicine. |
Examples of what published studies actually measure
| Compound | Model | Endpoint and source |
|---|---|---|
| BPC-157 | Rat tendon explants and cultured tendon fibroblasts | Outgrowth, migration and survival; proliferation was not directly increased in this experiment. Chang et al., 2011 |
| CJC-1295 | Healthy adults in two randomised placebo-controlled studies | GH and IGF-I responses; this was not a CJC-1295/ipamorelin combination trial. Teichman et al., 2006 |
| MOTS-c | Cell experiments and mouse metabolic models | Metabolic signalling and insulin-sensitivity measurements. Lee et al., 2015 |
| Tirzepatide | Authorised prescription medicine containing tirzepatide | Use and clinical evidence concern the authorised medicine and its product information. EMA: authorised tirzepatide medicine |
Use the complete methods section for the exact exposure and controls. A review or abstract can identify a useful study, but it cannot supply every detail needed to reproduce it. These examples are evidence summaries, not validated protocols for all catalogue products.
Reconstitution and stability checklist
- Confirm sequence or compound identity, salt form, batch, supplied amount and available analytical results.
- Select a solvent and pH compatible with the peptide and the assay. Check solubility on a small amount first.
- Record the stock concentration, dilution, vehicle control, exposure time and preparation date.
- Use the supplier’s stability instructions and validated laboratory storage conditions. Preservatives do not establish a universal 28–30 day peptide shelf life.
- Keep the experiment’s approval, safety assessment and disposal requirements with the laboratory record.
Storage and handling guide · How to read a certificate · Published lab reports
Compound and batch information
The catalogue pages show available sizes, the supplier destination and the analytical documents available for comparison. Match the offered batch with its report.
For questions about the listed product or documents: support@balticbiolabs.eu. Laboratory methods should be selected and validated by the responsible research team.